Drug intelligence / Profile preview

LC-PC01

Development stage: Preclinical
Lead developer: LISCure Biosciences
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

LC-PC01 is a live biotherapeutic product (LBP) being developed by LISCure Biosciences in collaboration with Celltrion for the treatment of Parkinson's disease. As a microbiome-based therapy, it is designed to modulate the gut-brain axis, potentially addressing neuroinflammation and other pathological features associated with neurodegenerative disorders. The program has demonstrated preclinical proof of concept (PoC) and is currently in the preclinical stage of development.

Beyond the preview

Go deeper on LC-PC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC-PC01.

Explore the full profile